Plasma GFAP did not significantly differ between A+T+ and A+T− ALS patients (p > 0.99), while the comparison between A−ALS patients and controls reached a trend of significance (p = 0.07) (Figure 1b). This evidence concerns the gene GFAP and amyotrophic lateral sclerosis.